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Summary Twenty-four evaluable patients with stage T4 breast cancer were entered into a phase II study and
received chemotherapy comprising cyclophosphamide 1,000 mg m-2 i.v., doxorubicin 50 mg m-2 i.v., vincris-
tine 1.4 mgm-2 i.v. and prednisolone 40mg orally for 5 days, given 3 weekly for four cycles prior to
undergoing loco-regional radiotherapy. All patients completed treatment as planned with no major acute
toxicity from either chemotherapy or radiotherapy. Subsequently 52 patients with stage T4 breast cancer were
randomised in a phase III trial to receive either radiotherapy alone (RT) or this chemotherapy and
radiotherapy (CHOP + RT). A significantly higher complete response rate was achieved in the CHOP + RT
treatment arm (P = 0.03). However a larger proportion of the RT arm achieved loco-regional control after
salvage treatment for relapse such that 50% of the RT arm and 57% of the CHOP + RT arm had no evidence
of loco-regional disease at the time of last follow-up or death. There was no statistical difference in time to
distant relapse or overall survival. Analysis of the pilot study showed results comparable to the trial
CHOP + RT arm. This trial suggests that this cytotoxic therapy used in conjunction with radiotherapy has
only marginal value in improving prognosis in locally advanced breast cancer.
In Western Europe and North America, it is accepted that
locally advanced breast cancer accounts for between 4-20%
of all cases seen (Rubens et al., 1977; Lopez et al., 1985).
Amongst new cases of breast cancer presenting in Edinburgh
during the course of 1 year, 24% of a random sample of
cases were found to be locally advanced tumours, indicating
that this stage of the disease is not uncommon (Roberts et
al., 1990). Locally advanced breast cancer corresponds
approximately to stage III in the TMN classification (UICC,
1987) in which are included T3/4 N (any) MO or T (any)
N2/3 MO tumours.
Locally advanced breast cancer presents a formidable man-
agement problem. The disease may apparently be localised at
presentation and although in some cases it may pursue an
indolent course, metastases commonly appear early, resulting
in an overall median survival of 25-30 months (Zucali et al.,
1976). In those patients who do not die early from meta-
stases, treatment has to be directed towards achieving and
maintaining local control.
Radiotherapy alone can achieve a response rate of 60-80%
(Griscom & Wang, 1962; Langlands et al., 1976). However,
remissions tend to be short and local control is prolonged in
only a minority of cases. In the above series, local complete
remission was maintained until death in 27-35% of cases
when the disease was treated solely with radiotherapy. When
higher doses of radiation are used to try and improve upon
such results, severe fibrosis and/or necrosis may occur
(Spanos et al., 1980).
The addition of chemotherapy prior to radiotherapy has a
number of theoretical advantages. The probability of local
control by radiotherapy depends on the number of residual
clonogenic cells (Tubiana, 1983) which can be reduced
beforehand by chemotherapy. This tumour shrinkage may
also reduce the proportion of hypoxic cells in the tumour
that could otherwise contribute to radio-resistance (Thomlin-
son & Gray, 1955). Furthermore, these patients are at high
risk of having micrometastases. Improved survival has been
attributed to the use of adjuvant cytotoxic therapy in early
breast cancer (Early Breast Cancer Trialists Collaborative
Group, 1989). A similar improvement in survival might be
expected from the use of systemic therapy in patients with
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locally advanced breast cancer, even though the disease
population and chemosensitivity may be different. Chemo-
therapy may also increase the proportion of cases which are
rendered operable (DeLena et al., 1978).
In the treatment of systemic disease, combination chemo-
therapy gives better disease control than single agents (Lyss
& Loeb, 1984) but at the cost of increased toxicity. The
anthracycline, doxorubicin, is the single most active agent
available for the treatment of breast cancer with an overall
objective response rate of 40-50% (Harris et al., 1985),
which can be increased to approximately 70% when used in
combination with cyclophosphamide and vincristine (Rainey
et al., 1979). We have tested the feasibility of using combina-
tion chemotherapy, utilising these drugs, in the treatment of
locally advanced breast cancer immediately prior to loco-
regional radiotherapy in a phase II study; and then compared
this approach with loco-regional radiotherapy alone in a
prospective, randomised, controlled clinical trial, having
established that the combined approach treatment did not
cause unacceptable toxicity.
Patients and methods
The phase II study was initiated in January 1982. Twenty-
four evaluable patients with locally advanced breast cancer
were treated with four cycles of combination chemotherapy
before proceeding to loco-regional radiotherapy. The pro-
spective randomised trial was opened in January 1984 and
continued to April 1989 by which time 52 patients had been
randomised.
All patients in both the phase II study and in the trial were
staged using UICC TNM (1978) criteria and had previously
untreated inoperable breast cancer staged as T4, or with fixed
axillary nodes (N2) or supraclavicular node involvement
(N3). Patients were excluded if they had bilateral breast
cancer, metastatic disease (M1) or a history of previous
therapy for breast cancer. A history of successfully treated
cancer at other sites did not exclude the patient. Patients
aged 70 years or over and those who were deemed medically
unfit for intensive chemotherapy or radical radiotherapy were
excluded.
A clinical assessment was made of tumour size and stage in
all patients and bilateral mammograms were also performed.
A chest X-ray, bone scan and liver function tests were under-
taken to exclude systemic disease. If liver function was dis-
turbed, an ultrasound scan was performed to confirm/exclude
Br. J. Cancer (1992), 65, 761-765 '." Macmillan Press Ltd., 1992762 A. RODGER et al.
hepatic metastases. A biopsy of the primary tumour or nodal
disease was carried out in each patient to provide a histo-
logical diagnosis and an assessment of oestrogen receptor
(ER) content.
These same eligibility criteria applied for entry to the trial.
If a patient fulfilled these criteria, a randomised treatment
option was obtained through the Scottish Cancer Trials Office.
Patients were stratified into four groups by menstrual status
(premenopausal: postmenopausal) and by receptor status
(ER <20 fmol mg-' protein: ER>20 fmol mg-' protein)
and randomised to receive either loco-regional radiotherapy
alone (RT alone) or loco-regional radiotherapy preceeded by
chemotherapy (CHOP + RT).
Patients randomised to receive chemotherapy (CHOP)
were given four cycles of a combination of intravenous
chemotherapy on day 1 including: cyclophosphamide 1,000
mgm2 adriamycin 50 mgm2 and vincristine 1.4mgM2
(to a maximum dose of 2mg). Oral prednisolone, 40mg
daily, was given on days 1-5. The interval between cycles
was 21 days. Dose modifications permitted within the pro-
tocol included: a delay of 1 week in the presence of mild
(WHO grade 1) haematological toxicity; reduced doses (by
50%) of cyclophosphamide and doxorubicin with grade 2
haematological toxicity; and omission of vincristine in the
presence of grade 2 or greater neurotoxicity.
Megavoltage radiotherapy was administered to the breast
by the use of a pair of wedged fields applied tangentially
across the chest wall utilising skin bolus. The peripheral
lymphatics were treated with an anterior cervico-axillary field
in conjunction with a posterior axillary field. If the tumour
lay on the junction of these fields, a jig and bolus technique
was used in which a single pair of large fields treated the
breast and axilla in continuity. Irrespective of technique, the
prescribed dose to the breast and to the mid-plane of the
axilla was 45 Gray in 20 fractions. Where possible the pri-
mary site was boosted by either an interstitial radio-active
iridium implant, giving a dose of 25-30 Gray to the refer-
ence isodose, or by electron/orthovoltage therapy giving a
dose of 15 Gray in five fractions. When this was not prac-
ticable due to widespread disease throughout the breast, a
higher dose of 50 Gray in 20 fractions was given to the whole
breast using megavoltage X-rays. An axillary boost was given
where there was evidence of residual lymphadenopathy or if
bulky axillary disease had been present initially.
Response was assessed as complete remission, partial
remission, stable disease or progressive disease by standard
criteria (Hayward et al., 1977). Survival was measured from
date of randomisation for trial patients and date of first
treatment for patients in the phase II study. The minimum
follow-up period in the phase II study is 6 years. In the trial
the follow-up period ranges from 21 months to 6 years.
Results
In the trial, there were two protocol violations and one
patient was randomised in error. One of these patients was
randomised to receive CHOP + RT but refused chemotherapy
and was subsequently treated by radiotherapy alone. Another
was randomised to receive radiotherapy alone, but developed
rapidly progressive inflammatory breast cancer before treat-
ment could begin. The disease was too extensive to be treated
by orthodox radiotherapy and the patient was treated with
chemotherapy. The third patient was found to have thicken-
ing in the contralateral breast at presentation. The area was
excised and initially reported histologically as benign. The
patient was randomised to the CHOP + RT arm. Subse-
quently, however, a revised report was issued to say that a
small focus of invasive carcinoma had been identified in the
specimen. This patient despite having bilateral breast disease
was treated as randomised within the trial. Of the remaining
49 patients, 26 were randomised to receive CHOP + RT and
23 RT alone. All patients are included and are analysed
according to their randomised treatment selection irrespective
of the treatment received.
Characteristics of patients in the phase II study and the
trial including age, menstrual status, oestrogen receptor
levels, clinical size, degree of skin involvement and node
stage are shown in Table I. The number of patients with no
clinical involvement of axillary lymph nodes was similar in
the two trial groups. However, there were more patients with
fixed axillary lymph nodes (N2) in the RT alone group than
in the CHOP + RT group, although, in contrast, the latter
group did contain all patients admitted to the study who
were considered to have involvement of ipsilateral supra-
clavicular lymph nodes (N3). In the trial, all patients had
T4b disease on the basis of oedema (including peau d'orange),
infiltration or ulceration of skin of the breast. In each group,
one patient also had disease fixed to the chest wall (T4c). No
patient had oedema of the arm at presentation.
In the phase II study, all patients received four courses of
CHOP chemotherapy. Five patients experienced some delay:
three due to low blood counts, one because of an infection
and one for an unrecorded reason. Six patients had moder-
ately severe symptoms and seven mild symptoms, mainly of
the gastro-intestinal tract. All patients developed complete
alopecia. Two patients, both of whom received 50 Gray in 20
fractions to the breast, developed confluent moist desquama-
tion (RTOG/EORTC grade 3); eight other patients develop-
ed bright erythema or patchy moist desquamation of the skin
(RTOG/EORTC grade 2), and the remaining 14 patients
developed a minimal acute radiation skin reaction (RTOG/
EORTC grade 0-1). None of the acute radiation skin re-
actions were considered to be more severe than expected for
radiotherapy alone. No patient developed symptomatic
radiation pneumonitis.
In the trial, of the 28 patients in the CHOP + RT group
one refused all chemotherapy while two patients refused
further chemotherapy after two courses, one for psycho-
logical reasons and the other following moderately severe
side-effects including haematological toxicity. The other 25
patients received four courses of CHOP. No delay or dose
Table I Patient characteristics
Phase II
CHOP + RT RT alone study
Total number of patients 28 24 24
Age
mean (years) 54.5 55.6 55.3
range (years) 40-67 34-69 37-68
Menstrual status/ER level
Premenopausal
ER<20 8 6 2
ER,20 4 2 5
Postmenopausal
ER<20 7 6 8
ER>20 9 10 5
ER not known 0 0 4
Clinical size - maximum
diameter (cm)
<5 6 3 1
)5- <7.5 13 13 15
>7.5-<10 7 4 6
)10 1 4 1
not recorded 1 0 1
Skin involvement
oedema only 18 11
infiltration±oedeam 7 10
ulceration + infiltration 3 2
satellite nodules + 0 1
oedema
Fixation to chest wall and
skin involvement (T4c) 1 I
Clinical node stage
NO/Nla 7 7 6
Nlb 16 6 13
N2 2 11 5
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modification was required in 21, although two developed
mild haematological toxicity. Three patients had one cycle
delayed, one because of an upper gastro-intestinal upset and
one because of suspected disease progression. A fourth
patient had two cycles delayed and three cycles modified
because of haematological toxicity (grade 4). Three patients
developed mild and one moderate neurological toxicity. Skin
reactions after radiotherapy were not formally graded, but no
excessively severe reactions were noted.
The maximum tumour response was assessed after chemo-
therapy and before radiotherapy in both the phase II study
and the CHOP + RT trial arm, and after radiotherapy in all
patients. This information is shown in Table II.
In the phase II study, five patients (20.8%) achieved com-
plete response following chemotherapy alone but this in-
creased to 16 patients (66.7%) after radiotherapy. During the
period of follow-up, six patients relapsed so that ten patients
(41.7%) maintained loco-regional control by primary therapy
alone at the time of last follow-up or death.
In the randomised trial, in the CHOP + RT group, five
(17.8%) achieved complete remission following chemo-
therapy alone. Again this increased to 22 patients (78.6%)
after radiotherapy. In the RT alone arm, 11 patients (45.8%)
achieved complete remission with primary treatment. The
complete response rate following combined modality treat-
ment is significantly higher (P = 0.03). During the period of
follow-up, ten patients who had achieved complete remission
in the CHOP + RT arm, and seven patients in the RT alone
arm, developed loco-regional relapse. The loco-regional con-
trol rate by primary therapy alone at the time of last follow-
up or death is therefore 42.8% for the CHOP + RT group
and 16.7% for the RT alone group (P = 0.08).
Table II Tumour response
CHOP + RT RT alone Phase II
(28) (24) study (24)
Response after CHOP
before RT
complete response 5 (17.8%) - 5 (20.8%)
partial response 11 (39.3%) - 5 (20.8%)
static 9 (32.1%) - 13 (54.2%)
progression 3 (10.7%) - 1 (4.2%)
Response after CHOP and
RT
complete response 22 (78.6%) 11 (45.8%) 16 (66.7%)
partial response 5 (17.8%) 8 (33.3%) 6 (25.0%)
static 0 (0%) 3 (12.5%) 2 (8.3%)
progression 1 (3.6%) 2 (8.3%) 0 (0%)
Relapse after complete 10 (%) 7 (%) 6 (%)
response
Loco-regional control 12 (42.8%) 4 (16.7%) 10 (41.7%)
following primary
treatment
Loco-regional control 4 8 6
following secondary
salvage treatment
Overall loco-regional 16 (57.0%) 12 (50.0%) 16 (66.6%)
control at last follow-up
or death
Table III Median disease-free (loco-regional) interval for patients
achieving CR from primary treatment (Time in months. Number of
patients in ( ))
CHOP + RT RT alone Phase II study
Alive/dead relapsed 5.5 (10) 7.0 (7) 12.5 (6)
Range (2-35) (1-50) (12-41)
Dead never relapsed 8.0 (3) 16.0 (2) 14.5 (6)
Range (5-39) (8-24) (1-29)
Alive never relapsed 35.0 (9) 44.5 (2) 70.0 (4)
Range (19-69) (35-54) (70-80)
Table III demonstrates the median loco-regional disease-
free interval in both the phase II study and the trial seen by
those patients who achieved complete clinical remission fol-
lowing primary therapy. There is no evidence to suggest that
loco-regional control achieved by the CHOP + RT arm is
more durable than that of the RT alone arm.
Figures 1 and 2 show the survival curves for metastasis
free survival and overall survival in each of the trial arms
and in the phase II study. No significant differences are
observed.
Treatment of loco-regional or systemic relapse was not
specified in the trial protocol. Assessment for further treat-
ment of patients with partial response or relapse was under-
taken at a combined surgical/clinical oncology clinic. Further
therapy was determined on an individual basis depending on
such factors as medical condition, location of relapse and ER
status. Patients received a variety of therapies including
endocrine manipulation, chemotherapy and surgery. Most
patients received more than one form of secondary therapy
at some time in the management of their disease. A larger
proportion of patients in the RT arm achieved subsequent
local control of disease after relapse with the result that 50%
of patients had no evidence of loco-regional disease following
primary and secondary salvage therapies at the time of last
follow-up or death, compared with 57% of those patients in
the CHOP + RT arm. This difference is not significant. Table
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Table IV Loco-regional salvage therapy after either partial response
or relapse
CHOP + RT RT alone Phase II study
Surgery 2 4 3
Endocrine therapy 2 3 3
Chemotherapy 0 1 0
Total 4 8 6
further treatment which resulted in loco-regional control at
the last follow-up or death, i.e. successful salvage treatment,
along with the type of secondary treatment responsible.
Surgery - generally mastectomy - produced control of disease
loco-regionally in a total ofsix patients in the trial (and three
in the Phase II study) although the disease at presentation
was considered inoperable.
Discussion
Breast cancer is a moderately chemosensitive tumour with a
reaponse frequency of up to 70% when metastatic disease is
treated with modern combination chemotherapy. In both the
phase II study and the chemotherapy arm of the trial, the
overall response rate to chemotherapy immediately prior to
radiotherapy was well short of this at 57% and 42%, respec-
tively. This apparently disappointing response may be be-
cause patients proceeded with the minimum of delay to
treatment with radiotherapy with insufficient time allowed for
the full benefit of the chemotherapy to be realised. There
seems little room to argue about dose intensity of the two
best drugs in the regimen, adriamycin and cyclophospha-
mide. Collectively they were planned and, for most patients
given, at around 100% of the 'Gold Standard' regimen of
Bull et al. (1978) according to comparison with the data as
discussed by Hrynuik and Bush (1984) in an influential
review ofdose-intensity of chemotherapy for advanced breast
cancer. Objective assessment of chemotherapy-induced toxi-
city, including possible potentiation of radiation skin re-
actions in the phase II study, led us to conclude that this
treatment caused little and acceptable morbidity and, in par-
ticular, did not increase acute radiation toxicity. This obser-
vation was subsequently confirmed in the clinical trial when
75% of patients completed chemotherapy without delay or
modification of any of the courses of treatment being neces-
sary.
The median survival of patients in the phase II study and
the trial ranges between 36 and 52 months. This is better
than would have been expected on the basis of earlier reports
(Zucali et al., 1976; Loprinzi et al., 1984) and must be a
reflection of the selection of patients entering these studies
rather than of any treatment effect. Possible reasons for this
may include stringent screening for metastatic disease with
isotope bone scintigraphy and ultrasound scanning of the
liver being performed routinely. All patients entering the trial
met the criteria of having stage T4b disease on the basis of
skin involvement. However, most patients demonstrated only
peau d'orange of the breast and did not have signs of skin
infiltration/ulceration or of satellite nodules. Only one patient
in each of the trial arms had disease fixed to the chest wall in
association with evidence of skin involvement (T4c). These
features may all contribute to an apparent improvement in
survival when comparison is made with other series.
Historical comparisons suggest that survival and local con-
trol rates can be improved when chemotherapy and radio-
therapy are used together in the primary management of
locally advanced breast cancer (DeLena et al., 1978; Rubens
et al., 1980). These observations have been tested in only a
few randomised, controlled clinical trials. One such study did
show a survival benefit (Grohn et al., 1984), but this has not
been confirmed by other trials (Rubens et al., 1989; Schaake-
Koning et al., 1985).
Our trial suggests that adjuvant chemotherapy and radio-
therapy used together in the primary management of stage
T4 breast cancer does produce a higher initial local remission
rate. However, this does not ultimately translate into a better
prognosis with respect to long-term loco-regional control,
metastases-free interval or overall survival. The fact that
patients treated solely with radiotherapy had a significantly
inferior initial local remission rate and yet a comparable
proportion of this group remained in complete local remis-
sion at the time of death or last follow-up following the use
of secondary treatment, supports a policy of treatment and
follow-up of such patients in specialist combined surgery/
clinical oncology clinics.
Experience from studies of early node positive breast
cancer (Ti -2, NI) in premenopausal women suggest that
chemotherapy does confer survival benefit although the mag-
nitude of this effect is relatively small and meta-analysis of all
available data obtained from many thousands of patients is
necessary in order to demonstrate it. It is likely that a similar
analysis will be required to study the same question in locally
advanced breast cancer. In this way data from studies such
as this, may contribute collectively as well as individually to
develop a more uniform approach to this problem in the
future.
The authors wish to express their appreciation to the staff of the
Scottish Cancer Trials Office (MRC) for assistance with trial ran-
domisations and to Miss Mhairi Speed for her help in preparing this
manuscript.
References
BULL, J.M., TORMEY, D.C., LI, S. & 5 others (1978). A randomised
comparison of adriamycin versus methotrexate in combination
drug therapy. Cancer, 41, 1649-1657.
DE LENA, M., ZUCALI, R., VIGANOTTI, G., VALAGUSSA, P. & BON-
NADONNA, G. (1978). Combined chemotherapy/radiotherapy
approach in locally advanced (T3b-T4) breast cancer. Cancer
Chemother. Pharmacol., 1, 53-59.
EARLY BREAST CANCER TRIALISTS COLLABORATIVE GROUP
(1988). Effects of adjuvant tamoxifen and cytotoxic therapy on
mortality in early breast cancer: an overview of 61 randomised
trials among 28,896 women. New Engl. J. Med., 319, 1681-1692.
GRISCOM, N.T. & WANG, C.C. (1962). Radiation therapy of inoper-
able breast carcinoma. Radiology, 79, 18-23.
GHOHN, P., HEINONEN, E., KLEFSTROM, P. & TARKANEN, J.
(1984). Adjuvant postoperative radiotherapy, chemotherapy, and
immunotherapy in stage III breast cancer. Cancer, 54, 670-674.
HARRIS, J.R., CANELLOS, G.P., HELLMAN, S. & FISHER, B. (1985).
Cancer of the breast. In Cancer: Principles and Practice ofOnco-
logy, DeVita, V.T. (ed.) p. 1156. Lippincott: Philadelphia.
HAYWARD, J.L., CARBONE, P.P., HENSON, J.C., KUMAOKA, S.,
SEGALOFF, A. & RUBENS, R.D. (1977). Assessment of responses
to therapy in advanced breast cancer. Cancer, 39, 1289-1294.
HRYNUIK, W. & BUSH, H. (1984). The importance of dose intensity
in chemotherapy of metastatic breast cancer. J. Clin. Oncol., 2,
1281-1288.
INTERNATIONAL UNION AGAINST CANCER (1978). TNM Classi-
fication of Malignant Tumours, 3rd edn. Geneva.
INTERNATIONAL UNION AGAINST CANCER (1987). TNM Classi-
fication of Malignant Tumours, 4th edn. Geneva.
LANGLANDS, A.O., KERR, G.R. & SHAW, S. (1976). The management
of locally advanced breast cancer by X-ray therapy. Clin. Oncol.,
2, 365-371.
LOPEZ, M.J., KRAYBILL, W.G., REYNOLDS, R.D. & KHOJASTEH, A.
(1985). Changing patterns in the management of locally advanced
breast cancer. Can. J. Surg., 28, 319-322.LOCALLY ADVANCED BREAST CANCER 765
LOPRINZI, C.L., CARBONE, P.P., TORMEY, D.C., ROSENBAUM, P.R.,
CALDWELL, W., KLINE, J.C. et al. (1984). Aggressive combined
modality therapy for advanced loco-regional breast carcinoma. J.
Clin. Oncol., 2, 157.
LYSS, A.P. & LOEB, V. (1984). Chemotherapy of advanced breast
cancer. Cancer, 53, 778-782.
RAINEY, J.M., JONES, S.E. & SALMON, S.E. (1979). Combination
chemotherapy for advanced breast cancer utilizing vincristine,
adriamycin and cyclophosphamide (VAC). Cancer, 43, 66-71.
ROBERTS, M.M., ALEXANDER, F.E., ELTON, R.A. & RODGER, A.
(1990). Breast cancer stage, social class and the impact of screen-
ing. Eur. J. Surg. Oncol., 16, 18-21.
RUBENS, R.D., SEXTON, S., TONG, D., WINTER, P.J., KNIGHT, R.K.
& HAYWARD, J.L. (1980). Combined chemotherapy and radio-
therapy for locally advanced breast cancer. Eur. J. Cancer, 16,
351-356.
RUBENS, R.D., ARMITAGE, P., WINTER, P.J., TONG, D. & HAY-
WARD, J.L. (1977). Prognosis in inoperable stage III carcinoma of
the breast. Eur. J. Cancer, 13, 805-811.
RUBENS, R.D., BARTELINK, H., ENGELSMAN, E. & 8 others (1989).
Locally advanced breast cancer: the contribution ofcytotoxic and
endocrine treatment to radiotherapy. Eur. J. Cancer Clin. Oncol.,
25, 667-678.
SCHAAKE-KONING, C., HAMERSMA VAN DER LINDEN, E., HART, G.
& ENGELSMAN, E. (1985). Adjuvant chemo- and hormonal
therapy in locally advanced breast cancer: a randomized clinical
study. Int. J. Radiat. Oncol. Biol. Phys., 11, 1759-1763.
SPANOS, W.J., MONTAGUE, E.D. & FLETCHER, G.H. (1980). Late
complications of radiation only for advanced breast cancer. Int.
J. Rad. Oncol. Biol. Phys., 6, 1473-1476.
THOMLINSON, R.H. & GRAY, L.H. (1955). The histological structure
of some human cancers and the possible implications for radio-
therapy. Br. J. Cancer, 9, 539-549.
TUBIANA, M. (1983). The causes of clinical radioresistance. In The
Biological Basis of Radiotherapy, Steel, G.G., Adams, G.E. &
Peckham, M.J. (eds), p. 13-33. Elsevier: Amsterdam.
ZUCALI, R., UNSLENGHI, C., KENDA, R. & BONNADONNA, G.
(1976). Natural history and survival of inoperable breast cancer
treated with radiotherapy and radiotherapy followed by radical
mastectomy. Cancer, 37, 1422-1431.